An investigation of serum irisin levels and iflammatory markers in fibromyalgia syndrome

OBJECTIVE: In the present study, we aimed to compare serum irisin levels in patients with fibromyalgia syndrome (FMS) and healthy control subjects and also investigate the relationship between irisin, disease activity and inflammation markers in patients

Serum Clara cell secretory protein (CC-16) in non-smoking patients with obstructive sleep apnea

Objective This study aimed to determine the association between the severity of obstructive sleep apnea (OSA) and serum Clara cell protein (CC16) levels in non-smoking patients with OSA. Methods This prospective study included non-smoking patients who presented with sleep-related disturbances and underwent polysomnography (PSG). The serum CC16 level was measured and its relationship to PSG parameters was investigated. Results The study included 128 patients (83 men) with a mean age of 48.4 +/- 11.9. OSA was detected in 66 men (70%) and 29 women (30%) (p = 0.051). The severity of OSA was mild in 32 (25%), moderate in 28 (22%), and severe in 35 (27%) of the patients. There was no significant difference in CC16 levels between the OSA group (1746 +/- 1006) and the OSA negative group (1721 +/- 1201,p = 0.91) levels. There was no significant difference between the CC16 levels of the each four groups. Mean serum CC16 levels were significantly lower in OSA negative men than OSA positive men (777 vs 1462,p = 0.005). No significant difference was observed in CC16 values according to OSA severity in women. Conclusion The serum CC16 level does not differ between non-smoking OSA patients and OSA negative patients.WOS:0005623130000012-s2.0-85081686113PubMed: 3214459

The effects of smoking on the placentas of smoker mothers in terms of MPO, MMP-9 and FGF

6th World Congress of Oxidative Stress, Calcium Signaling and TRP Channels -- MAY 24-27, 2016 -- Isparta, TURKEYAim: Smoking during pregnancy remains a common habit. Pregnant smokers harm both themselves and their fetus. Therefore, in this study, we aimed to investigate oxidative stress and angiogenic effects of smoking on pregnant smokers by analyzing FGF, MMP-9, and MPO levels. Material and Methods: The placentas of 68 pregnant women which referred to the pathology laboratory between the years 2010 and 2011 were included in the study. Of the total, 28 women were smokers (S) and 40 women were non-smokers (NS). The FGF, MMP-9, and MPO immunostaining of placental tissues were examined by manual microarray study. The number of cigarettes smoked, age, systemic disease rate, mean abortus number, blood pressure, hemoglobin and hematocrit, Apgar, and pathological parameters were also evaluated. Results: Statistically significant positive relationships were found between S and NS groups in terms of MMP-9 staining (grade 1) (p=0.039). There was no MMP-9 staining in S group. Systemic diseases were more frequent in S than NS group (p=0.049). There was no statistically significant relationship between other parameters. Discussion: The effects of smoking on the fetus have been demonstrated with MMP-9. More comprehensive studies are needed to reveal the relationship between fetus and smoking.WOS:00057273950001

Serum levels of obestatin and adiponectin in patients with obstructive sleep apnea syndrome

Annakkaya, Ali Nihat N/0000-0002-7661-8830; Ayada, Ceylan/0000-0002-6272-4173WOS: 000364786400193

Serum levels of growth hormone in patients with obstructive sleep apnea syndrome

Annakkaya, Ali Nihat N/0000-0002-7661-8830; Ayada, Ceylan/0000-0002-6272-4173WOS: 000364786400190

Evaluation of Visfatin in Patients with Obesity, Metabolic Syndrome, Insulin Resistance and Impaired Glucose Tolerance; Case-Control Study

INTRODUCTION: Visfatin is a novel adipokine originally described to be produced predominantly by visceral fat tissue. The aim of the study was aimed to investigate visfatin level in non-diabetic obese patients with or without MetS and prediabetes. \ud METHODS: The cross-sectional study enrolled 169 subjects. Anthropometric measures and metabolic parameters were obtained. Exclusion criteria were pregnancy, smoking, any of the chronic disease. Blood sample was collected overnight fasting and centrifuged, and stored at refrigerator at -70º degree until to be assayed. Visfatin was assayed with ELISA method. \ud RESULTS: The study enrolled 169 subjects aged 36.9 ± 8.5 years (control group = 52 and obese group: 117; and Male: 28 and Female: 141). Among obese subjects, the frequency of MetS, and PreDM was respectively 35.1% (n = 41) and 70.1% (n = 82). Mean concentration of serum visfatin among subjects with obesity was significantly higher those with normal weight subjects (10.39 ± 2.30 versus 6.9 ± 2.2 ng/mL; p < 0.001). The subjects with IR+ (10.58 ± 2.48 ng/mL ) had significantly higher visfatin concentration than those with IR- (10.58 ± 2.48 ng/mL and 8.47 ± 2.65 ng/mL) (p < 0.001, respectively). Visfatin positively correlated with BMI (r = +0.627 and p < 0.001), WHR (r = +0.203 and p = 0.023), HOMA-IR (r = +0.329 and p < 0.001), and hs-CRP (r = +0.421 and p < 0.001). Mean concentration of serum visfatin was not significantly different between groups of MetS and PreDM. \ud DISCUSSION AND CONCLUSION: Visfatin was associated with body mass index and insulin resistance, but not with metabolic syndrome and impaired glucose metabolism